(MRNA) Moderna - Ratings and Ratios
Vaccines, Therapeutics, RNA Medicines, Oncology, Rare Disease Products
MRNA EPS (Earnings per Share)
MRNA Revenue
Description: MRNA Moderna
Moderna Inc (NASDAQ:MRNA) is a biotechnology company specializing in messenger RNA (mRNA) medicines, operating globally with a diverse portfolio of vaccines and therapeutics. The companys product pipeline includes respiratory vaccines, latent vaccines, enteric viruses, public health vaccines, and bacterial diseases vaccines, showcasing its broad capabilities in vaccine development.
In addition to its vaccine portfolio, Moderna is also focused on oncology therapeutics, such as individualized neoantigen therapy and checkpoint adaptive immune modulation therapy, as well as rare disease products, including treatments for conditions like propionic acidemia and cystic fibrosis. This diversification across various therapeutic areas highlights the companys commitment to leveraging its mRNA technology to address a wide range of medical needs.
Moderna has established strategic alliances and collaborations with numerous partners, including AstraZeneca, Merck & Co., Inc, and Vertex Pharmaceuticals Incorporated, among others. These partnerships are crucial for advancing its research and development efforts, as well as for commercializing its products. The companys collaborations with government agencies, such as the Biomedical Advanced Research and Development Authority, and non-profit organizations like The Bill & Melinda Gates Foundation, further underscore its commitment to addressing significant public health challenges.
From a financial perspective, Modernas market capitalization stands at approximately $13.3 billion, with a forward price-to-earnings ratio of 32.47. The companys return on equity (ROE) is currently negative, at -30.10%, indicating that it is still in an investment phase, with significant expenditures on research and development. Key performance indicators (KPIs) to monitor include revenue growth, particularly from its vaccine sales, R&D expenses as a percentage of revenue, and the progression of its pipeline products through clinical trials.
To further evaluate Modernas potential, its essential to consider its cash position, burn rate, and the overall competitive landscape in the biotechnology sector, particularly in the mRNA space. The companys ability to execute on its pipeline, manage its finances effectively, and navigate regulatory environments will be critical factors in determining its future success.
MRNA Stock Overview
| Market Cap in USD | 9,147m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2018-12-07 |
MRNA Stock Ratings
| Growth Rating | -86.0% |
| Fundamental | 18.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -71.0% |
| Analyst Rating | 3.22 of 5 |
MRNA Dividends
Currently no dividends paidMRNA Growth Ratios
| Growth Correlation 3m | -55.6% |
| Growth Correlation 12m | -86.7% |
| Growth Correlation 5y | -72% |
| CAGR 5y | -43.14% |
| CAGR/Max DD 3y | -0.49 |
| CAGR/Mean DD 3y | -0.83 |
| Sharpe Ratio 12m | -2.34 |
| Alpha | -86.59 |
| Beta | 0.753 |
| Volatility | 50.56% |
| Current Volume | 11917.9k |
| Average Volume 20d | 9779.9k |
| Stop Loss | 22.3 (-6.6%) |
| Signal | 0.22 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-2.90b TTM) > 0 and > 6% of Revenue (6% = 183.6m TTM) |
| FCFTA -0.34 (>2.0%) and ΔFCFTA -9.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 150.3% (prev 145.0%; Δ 5.26pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.22 (>3.0%) and CFO -2.70b > Net Income -2.90b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (388.0m) change vs 12m ago 1.04% (target <= -2.0% for YES) |
| Gross Margin 52.22% (prev 32.81%; Δ 19.41pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 22.10% (prev 32.09%; Δ -9.99pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -209.4 (EBITDA TTM -2.72b / Interest Expense TTM 14.0m) >= 6 (WARN >= 3) |
Altman Z'' 6.66
| (A) 0.38 = (Total Current Assets 6.17b - Total Current Liabilities 1.57b) / Total Assets 12.01b |
| (B) 0.69 = Retained Earnings (Balance) 8.25b / Total Assets 12.01b |
| (C) -0.21 = EBIT TTM -2.93b / Avg Total Assets 13.85b |
| (D) 3.17 = Book Value of Equity 8.27b / Total Liabilities 2.61b |
| Total Rating: 6.66 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 18.59
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -79.54% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.12 = 2.49 |
| 5. Debt/Ebitda -0.40 = -2.50 |
| 6. ROIC - WACC -35.59% = -12.50 |
| 7. RoE -27.46% = -2.50 |
| 8. Rev. Trend -68.06% = -5.10 |
| 9. EPS Trend -55.90% = -2.80 |
What is the price of MRNA shares?
Over the past week, the price has changed by -3.83%, over one month by -14.78%, over three months by -8.15% and over the past year by -65.48%.
Is Moderna a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MRNA is around 13.77 USD . This means that MRNA is currently overvalued and has a potential downside of -42.34%.
Is MRNA a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 17
- Sell: 3
- Strong Sell: 1
What are the forecasts/targets for the MRNA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 44.3 | 85.3% |
| Analysts Target Price | 44.3 | 85.3% |
| ValueRay Target Price | 15.3 | -36.1% |
Last update: 2025-09-15 04:40
MRNA Fundamental Data Overview
CCE Cash And Equivalents = 5.13b USD (Cash And Short Term Investments, last quarter)
P/E Forward = 32.4675
P/S = 2.9718
P/B = 0.9732
Beta = 1.928
Revenue TTM = 3.06b USD
EBIT TTM = -2.93b USD
EBITDA TTM = -2.72b USD
Long Term Debt = 1.04b USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 43.0m USD (from shortTermDebt, last quarter)
Debt = 1.08b USD (Calculated: Short Term 43.0m + Long Term 1.04b)
Net Debt = -538.0m USD (from netDebt column, last quarter)
Enterprise Value = 5.10b USD (9.15b + Debt 1.08b - CCE 5.13b)
Interest Coverage Ratio = -209.4 (Ebit TTM -2.93b / Interest Expense TTM 14.0m)
FCF Yield = -79.54% (FCF TTM -4.05b / Enterprise Value 5.10b)
FCF Margin = -132.5% (FCF TTM -4.05b / Revenue TTM 3.06b)
Net Margin = -94.87% (Net Income TTM -2.90b / Revenue TTM 3.06b)
Gross Margin = 52.22% ((Revenue TTM 3.06b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Tobins Q-Ratio = 0.62 (Enterprise Value 5.10b / Book Value Of Equity 8.27b)
Interest Expense / Debt = 0.09% (Interest Expense 1.00m / Debt 1.08b)
Taxrate = 21.0% (US default)
NOPAT = -2.93b (EBIT -2.93b, no tax applied on loss)
Current Ratio = 3.93 (Total Current Assets 6.17b / Total Current Liabilities 1.57b)
Debt / Equity = 0.12 (Debt 1.08b / last Quarter total Stockholder Equity 9.40b)
Debt / EBITDA = -0.40 (Net Debt -538.0m / EBITDA -2.72b)
Debt / FCF = -0.27 (Debt 1.08b / FCF TTM -4.05b)
Total Stockholder Equity = 10.57b (last 4 quarters mean)
RoA = -24.17% (Net Income -2.90b, Total Assets 12.01b )
RoE = -27.46% (Net Income TTM -2.90b / Total Stockholder Equity 10.57b)
RoCE = -25.24% (Ebit -2.93b / (Equity 10.57b + L.T.Debt 1.04b))
RoIC = -27.72% (NOPAT -2.93b / Invested Capital 10.57b)
WACC = 7.87% (E(9.15b)/V(10.23b) * Re(8.79%)) + (D(1.08b)/V(10.23b) * Rd(0.09%) * (1-Tc(0.21)))
Shares Correlation 3-Years: -15.39 | Cagr: -0.54%
Discount Rate = 8.79% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -4.05b)
EPS Correlation: -55.90 | EPS CAGR: -16.27% | SUE: 0.28 | # QB: False
Revenue Correlation: -68.06 | Revenue CAGR: -67.86%
Additional Sources for MRNA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle